hospitals, included 6.5 million unweighted adult hospitalizations in 2010. 4 We used 2 approaches to identify patients with sepsis from International Statistical Classification of Diseases, Ninth Revision, Clinical Modification codes. The explicit approach identified those with codes 038 (septicemia), 995.91 (sepsis), 995.92 (severe sepsis), or 785.52 (septic shock). Because of the known underrecognition of sepsis, we also used an implicit approach adding patients with evidence of both infection and acute organ failure using the Angus implementation 5 of sepsis consensus criteria. Within KPNC data, we delineated diagnoses when coded as present on admission, an important consideration for improving identification and treatment efforts. Furthermore, we linked 97.9% (n = 19 621) of all explicit sepsis cases present on admission in 2012 to KPNC quality improvement data, permitting stratification of patients by common sepsis severity criteria including early goal-directed therapy (EGDT) eligibility and serum lactate levels.
6
In each cohort, we calculated the percentage of all inpatients admitted with sepsis, the sepsis hospital mortality rate, and the percentage and 95% confidence interval of hospital deaths occurring in patients with sepsis using Stata version 11.2 (StataCorp). The KPNC institutional review board approved the use of KPNC data with a waiver of informed consent and exempted NIS data from review.
Results | In the KPNC cohort, there were between 55 008 explicit (11.4% of total; 95% CI, 11.3%-11.5%) and 80 678 implicit (16.7%; 95% CI, 16.6%-16.8%) sepsis hospitalizations ( (Table 2) , patients with sepsis meeting criteria for EGDT (n = 2536) comprised 32.6% (95% CI, 30.4%-34.7%) of sepsis deaths. In contrast, patients with sepsis, normal blood pressure, and measured lactate levels of less than 4 mmol/L (n = 15 095) comprised 55.9% (95% CI, 53.6%-58.1%) of sepsis deaths.
Discussion | In 2 complementary hospital cohorts, we found that sepsis contributed to 1 in every 2 to 3 deaths, and most of these patients had sepsis at admission. Given the prominent role it plays in hospital mortality, improved treatment of sepsis (po- tentially a final hospital pathway for multiple other underlying conditions) could offer meaningful improvements in population mortality.
Patients with initially less severe sepsis made up the majority of sepsis deaths. Performance improvement efforts in the treatment of sepsis have primarily focused on standardizing care for the most severely ill patients, whereas interventions for treating other patients with sepsis are less well defined. Given their prevalence, improving standardized care for patients with less severe sepsis could drive future reductions in hospital mortality.
Even though our findings were broadly consistent, the study's primary limitation results from potential inaccuracies and inconsistencies in case identification across cohorts. Prior strategies, based on administrative data, have demonstrated variability with respect to prevalence estimates and case accuracy, a factor that may have contributed to differences between cohorts in explicit sepsis mortality.
5 Thus, we present granular data from the KPNC sepsis quality improvement program whose components include standardized case identification, manual chart validation, severity of illness risk adjustment, and treatment data; replication in other samples with similar granularity could be valuable. A review of eAppendix 1, which lists the exclusion criteria used for selecting healthy controls from the NHANES population, suggests that many individuals who might have been accepted as donors were excluded from the control group. These exclusions included any history of asthma, any cancer besides skin cancer, hypertension, and kidney stones. Selected patients with hypertension and kidney stones are not infrequently accepted as donors. 3, 4 We argue that a history of mild asthma or a remotely treated thyroid malignancy would not preclude donation. Similarly, functional limitations such as difficulty managing money or requiring special eating utensils were listed as exclusion criteria for NHANES controls, even though such limitations in isolation may not preclude live donation. These exclusions made the control group healthier and less likely to develop ESRD, thus biasing the findings in the direction of greater ESRD risk for donors. We appreciate the difficulty in finding ideal controls in determining outcomes of live kidney donation, especially from retrospective data. Prior studies of kidney donors 5 have been criticized as providing excessive reassurance about donor outcomes because the control populations did not exclude persons with diabetes and other individuals who would have been excluded from donation. The study by Muzaale et al 1 appears biased in the opposite direction, by excluding many individuals from the control group who might have been allowed to donate. As the authors pointed out, the magnitude of increased ESRD risk among donors was small-we suspect this risk is even smaller than reported and believe these findings should not discourage the many potential kidney donors for whom donation is safe.
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